Metoprololsuccinat Dura

Metoprolol, the active ingredient in Metoprololsuccinat Dura, is a beta blocker presented as an oral tablet for oral use. It treats hypertension, angina pectoris, heart failure and certain cardiac arrhythmias in adult patients.

GNH USA supplies Metoprololsuccinat Dura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprololsuccinat Dura is a beta‑adrenergic blocker used in cardiovascular disease management. - Hypertension: lowers systemic blood pressure by reducing cardiac output and inhibiting renin release. - Angina pectoris: decreases myocardial oxygen demand through heart‑rate and contractility reduction. - Heart failure: improves survival and symptoms by attenuating sympathetic overactivity. - Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other supraventricular tachyarrhythmias.

Metoprolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Cold extremities - Gastrointestinal upset (nausea, abdominal discomfort) - Sleep disturbances or vivid dreams

Serious or Rare Side Effects: - Bradycardia or severe heart block - Hypotension with syncope - Worsening heart failure - Bronchospasm in patients with asthma - Severe allergic reactions (rash, angioedema)

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Cardiovascular assessment: evaluate baseline heart rate, blood pressure, and cardiac function. - Respiratory status: avoid in uncontrolled asthma or severe chronic obstructive pulmonary disease. - Diabetes monitoring: watch for masking of hypoglycaemic symptoms. - Concomitant depression: monitor for worsening mood or suicidal thoughts. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at below 25°C: keep in original container, protect from moisture and direct sunlight.

Metoprolol may interact with several drug classes, altering its efficacy or safety.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): profound AV‑node depression. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): increased metoprolol plasma levels.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: potential masking of hypoglycaemia. - NSAIDs: may reduce antihypertensive effect. - Diuretics: risk of orthostatic hypotension. - Antidepressants (tricyclics): enhanced cardiac conduction effects.